Patents by Inventor Olga Khorkova

Olga Khorkova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
    Patent number: 9394542
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorder associated with the expression of DLG.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: July 19, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
    Patent number: 9382543
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural antisense polynucleotides of Pyrroline-5-carboxylate reductase 1 (PYCR1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PYCR1.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: July 5, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
    Patent number: 9382538
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CSF3.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: July 5, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF INSULIN GENE (INS) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN INSULIN GENE (INS)
    Publication number: 20160168574
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Insulin Gene (INS).
    Type: Application
    Filed: December 2, 2015
    Publication date: June 16, 2016
    Inventors: JOSEPH COLLARD, Olga Khorkova Sherman
  • TREATMENT OF ADIPONECTIN (ADIPOQ) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ADIPONECTIN (ADIPOQ)
    Publication number: 20160168568
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisaese oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF
    Publication number: 20160138023
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNP), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.
    Type: Application
    Filed: May 28, 2015
    Publication date: May 19, 2016
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IDUA
    Publication number: 20160130584
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.
    Type: Application
    Filed: October 28, 2015
    Publication date: May 12, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman, Carlos Coito, Gang Shen
  • TREATMENT OF DELTA-LIKE 1 HOMOLOG (DLK1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLK1
    Publication number: 20160090599
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression (DLK1).
    Type: Application
    Filed: November 19, 2015
    Publication date: March 31, 2016
    Inventors: JOSEPH COLLARD, Olga Khorkova Sherman, Carlos Coito
  • Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
    Patent number: 9290766
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.
    Type: Grant
    Filed: April 25, 2015
    Date of Patent: March 22, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
    Patent number: 9267136
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Pancreatic Developmental gene, in particular, by targeting natural antisense polynucleotides of a Pancreatic Developmental gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Pancreatic Developmental genes.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: February 23, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF SEX HORMONE BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SHBG
    Publication number: 20160046942
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sex Hormone Binding Globulia (SHBG), in particular, by targeting natural antisense polynucleotides of Sex Hormone Binding Globulin (SHBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SHBG.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
    Publication number: 20160024506
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of the antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 28, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
    Publication number: 20160024505
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 28, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • TREATMENT OF TRISTETRAPROLINE (TTP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TTP
    Publication number: 20160010092
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TTP.
    Type: Application
    Filed: September 9, 2015
    Publication date: January 14, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
    Patent number: 9234199
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Insulin Gene (INS).
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: January 12, 2016
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR PEPTIDASE, SITE 1 (MBTPS1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO MBTPS1
    Publication number: 20160002640
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
    Patent number: 9222088
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 29, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Gang Shen
  • TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1
    Publication number: 20150368644
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon-related tested developmental regulator 1 (IFRD1), in particular, by targeting natural antisense polynucleotides of interferon-related developmental regulator 1 (IFRD1). The invention also relates to the identification of these antisense oligonucleotides and their use in framing diseases and disorders associated with the expression of IFRD1.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 24, 2015
    Inventors: Joseph COLLARD, Olga Khorkova Sherman, Carlos Coito
  • Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
    Patent number: 9200277
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sex Hormone Binding Globulin (SHBG), in particular, by targeting natural antisense polynucleotides of Sex Hormone Binding Globulin (SHBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SHBG.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: December 1, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF ANTIVIRAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ANTIVIRAL GENE
    Publication number: 20150337307
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Antiviral gene, in particular, by targeting natural antisense polynucleotides of an Antiviral gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating disease and disorders associated with the expression of Antiviral genes.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Inventors: Joseph COLLARD, Olga Khorkova Sherman